arrow
V

Vanessa A. Fabrizio

children's hospital colorado
H指数:12
被引数:631

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL

HLH样综合征与儿童B-ALL患者CAR T治疗后死亡风险增加及CD19阴性复发相关

2026-07-210
OA
Linking HLA-DRB1*15 to Severe Dress-like Inflammatory Toxicities Following Tocilizumab after CAR-T Therapy

将HLA-DRB1*15与托珠单抗治疗后的CAR-T疗法相关严重DRESS样炎症性毒性反应相联系

2026-03-100
PRE
Phase II One Arm Multicenter Study of Early Reinfusion of Tisagenlecleucel to Promote Durable B-cell Aplasia in Pediatric and Young Adult Patients with relapsed/refractory CD19-Positive B-cell Acute Lymphoblastic Leukemia (REFUEL)
2026-02-030
PRE
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults

采集时外周血 blasts 作为 tisagenlecleucel 治疗后儿童和年轻患者生存的风险因素

2026-01-010
OAAI
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study

急性毒性和串联自体干细胞移植在儿童高危神经母细胞瘤中的早期结果:一项多中心研究

2025-11-120
PRE
Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

放宽接受Tisagenlecleucel治疗的低负担B-ALL儿童/青年患者的医院邻近要求

2025-10-030
OAAI
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis

tisagenleucel治疗后B-Cell ALL患者感染的实时世界结局:一项CIBMTR分析

2025-08-050
OAAI
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel

儿科患者接受tisagenlecuecel治疗时血液毒性的表征与预测

2025-07-230
OAAI
Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

B细胞恢复在复发风险和CD19表型中的作用:tisagenlecleucel用于儿童B淋巴细胞急性白血病真实世界应用的多机构回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
2023-11-012
OAAI
Mediport use as an acceptable standard for CAR T cell infusion
2023-10-270
OAAI
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
2023-06-156
OAAI
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
2023-02-1729
OAAI
Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force

监测儿科细胞治疗或造血细胞移植后的神经认知功能: COG细胞治疗神经认知工作组指南

2022-10-017
OAAI
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

最佳氟达拉滨淋巴细胞耗竭与CAR T细胞治疗后结局改善相关

2022-03-2557
OAAI
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report

复发/难治性髓外ALL的Tisagenlecleucel结局: 儿科真实世界CAR联盟报告

2022-01-2141
OAAI